In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Hold rating on Xoma Corp (XOMA). The company’s shares closed yesterday at $13.23, close to its 52-week low of $11.02.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 9.3% and a 51.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.
Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $28.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.99 and a one-year low of $11.02. Currently, Xoma Corp has an average volume of 49.29K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
